Across TCGA pan-cancer cohorts, ARMCX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARMCX2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ARMCX2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARMCX2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

LSCC, LUAD, and GBM are the cancer types where ARMCX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	II,III,IV	0.622	0.948	.007	15	view →
LUAD	DFS	Tertile	II,III,IV	0.698	1.000	.004	9	view →
GBM	OS	Quartile	All	0.832	0.979	.024	5	view →
OV	DFS	Median	All	0.682	0.923	.047	4	view →
PDAC	OS	Tertile	III,IV	1.000	0.527	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ARMCX2 tumor-vs-normal RNA expression · all ARMCX2 data types